Angiotensin II: A new therapeutic option for vasodilatory shock

Therapeutics and Clinical Risk Management

Volumn 14, Issue , 2018, Pages 1287-1298

  Bussard, Rachel L ^a   Busse, Laurence W ^a,b  

^a St Joseph's Hospital   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamine resistance; Refractory shock

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD PRESSURE; CARDIOGENIC SHOCK; DRUG MECHANISM; DRUG OVERDOSE; EXTRACORPOREAL CIRCULATION; HUMAN; LIVER FAILURE; NONHUMAN; REFRACTORY SHOCK; REVIEW; SHOCK; VASODILATATION; VASODILATORY SHOCK;

EID: 85058470976     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S150434     Document Type: Review

References (131)

1. Vincent J-L, de Backer D. Circulatory Shock. N Engl J Med Overseas Ed. 2013;369(18):1726–1734.
2. de Backer D, Biston P, Devriendt J, et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. N Engl J Med Overseas Ed. 2010;362(9):779–789.
3. Schmittinger CA, Torgersen C, Luckner G, Schröder DCH, Lorenz I, Dünser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012; 38(6):950–958.
4. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine Vasopressin in Advanced Vasodilatory Shock: A Prospective, Randomized, Controlled Study. Circulation. 2003;107(18):2313–2319.
5. Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;33(9):Cd003709.
6. Busse LW, Mccurdy MT, Ali O, Hall A, Chen H, Ostermann M. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Critical Care. 2017;21(1):324.
7. Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of Refractory Vasodilatory Shock. Chest. Epub 2018 Jan 9.
8. Bassi E, Park M, Azevedo LCP. Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock. Crit Care Res Pract. 2013;2013(2): 654708–654710.
9. Luckner G, Dünser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005; 33(11):2659–2666. 1294
10. Brown SM, Lanspa MJ, Jones JP, et al. Survival After Shock Requiring High-Dose Vasopressor Therapy. Chest. 2013;143(3):664–671.
11. Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med. 2007;35(10):2280–2285.
12. Torgersen C, Dünser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med. 2010;36(1): 57–65.
13. Benbenishty J, Weissman C, Sprung CL, Brodsky-Israeli M, Weiss Y. Characteristics of patients receiving vasopressors. Heart & Lung: The Journal of Acute and Critical Care. 2011;40(3):247–252.
14. Jenkins CR, Gomersall CD, Leung P, Joynt GM. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesth Intensive Care. 2009;37(2):286–289.
15. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377.
16. Mayr VD, Dünser MW, Greil V, et al. Causes of death and determinants of outcome in critically ill patients. Critical Care. 2006;10(6): R154.
17. Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. J Cardiovasc Pharmacol Ther. 2015;20(3):249–260.
18. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22(7):707–710.
19. Dünser MW, Ruokonen E, Pettilä V, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Critical Care. 2009;13(6):R181.
20. Dünser MW, Hasibeder WR. Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress. J Intensive Care Med. 2009;24(5):293–316.
21. Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med. 2016;42(9):1387–1397.
22. Asfar P, Meziani F, Hamel J-F, et al. High versus Low Blood-Pressure Target in Patients with Septic Shock. N Engl J Med Overseas Ed. 2014; 370(17):1583–1593.
23. Sviri S, Hashoul J, Stav I, van Heerden PV. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care. 2014;29(1):157–160.
24. Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36(12):2019–2029.
25. Hosseinian L, Weiner M, Levin MA, Fischer GW. Methylene Blue: Magic Bullet for Vasoplegia? Anesth Analg. 2016;122(1):194–201.
26. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937–1949.
27. Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Critical Care. 2014;18(5):534.
28. Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Critical Care. 2009;15(4):226.
29. Walley KR. Heterogeneity of oxygen delivery impairs oxygen extraction by peripheral tissues: theory. J Appl Physiol. 1996;81(2):885–894.
30. de Backer D, Creteur J, Dubois M-J, et al. The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med. 2006;34(2):403–408.
31. de Backer D, Creteur J, Silva E, Vincent J-L. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med. 2003;31(6):1659–1667.
32. Asfar P, Russell JA, Tuckermann J, Radermacher P. Selepressin in Septic Shock: A Step Toward Decatecholaminization? Crit Care Med. 2016;44(1):234–236.
33. Chawla LS, Busse LW, Brasha-Mitchell E, Alotaibi Z. The use of angiotensin II in distributive shock. Critical Care. 2016;20(1): 137.
34. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med. 2018;46(6):949–957.
35. Russell JA, Walley KR, Singer J, et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. N Engl J Med Overseas Ed. 2008;358(9):877–887.
36. Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med Overseas Ed. 2017;377(5): 419–430.
37. Russell JA, Lee T, Singer J, Boyd JH, Walley KR. The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience. Crit Care Med. 2017;45(6):940–948.
38. Szerlip H, Bihorac A, Chang S, et al. Effect of disease severity on survival in patients receiving angiotensin II for vasodilatory shock. Crit Care Med. 2018;46(1):3–868.
39. Mccurdy MB, Gong L, Boldt M, et al. Association of angiotensin II dose with all-cause mortality in patients with vasodilatory shock. Critical Care. 2018;22(Suppl 1):82.
40. Busse LW, Wang XS, Chalikonda DM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med. 2017;45(8):1285–1294.
41. Fournier D, Luft FC, Bader M, Ganten D, Andrade-Navarro MA. Emergence and evolution of the renin–angiotensin–aldosterone system. J Mol Med. 2012;90(5):495–508.
42. Kuntz A. The evolution of the sympathetic nervous system in vertebrates. J Comp Neurol. 1911;21(3):215–236.
43. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7): 247–257.
44. Zhuo JL, Li XC, Xc L. New insights and perspectives on intrarenal renin-angiotensin system: Focus on intracrine/intracellular angiotensin II. Peptides. 2011;32(7):1551–1565.
45. Rolih CA, Ober KP. The endocrine response to critical illness. Med Clin North Am. 1995;79(1):211–224.
46. du Cheyron D, Lesage A, Daubin C, Ramakers M, Charbonneau P. Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failure. Intensive Care Med. 2003;29(10): 1703–1709.
47. Hall A, Busse LW, Ostermann M. Angiotensin in Critical Care. Critical Care. 2018;22(1):69.
48. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201–1228.
49. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45(2):205–251.
50. Kurtz A, Pfeilschifter J, Hutter A, et al. Role of protein kinase C in inhibition of renin release caused by vasoconstrictors. Am J Physiol Cell Physiol. 1986;250(4):C563–C571.
51. Margolius HS. Kallikreins and Kinins: Molecular Characteristics and Cellular and Tissue Responses. Diabetes. 1996;45(Suppl 1):S14–S19.
52. Donoghue M, Hsieh F, Baronas E, et al. A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circ Res. 2000;87(5):e1–e9.
53. Ferrario CM, Brosnihan KB, Diz DI, et al. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension. 1991;18(5_Suppl): III126–III133.
54. Paul M, Poyan Mehr A, Kreutz R. Physiology of Local Renin-Angiotensin Systems. Physiol Rev. 2006;86(3):747–803.
55. Shenoy SK, Lefkowitz RJ. Angiotensin II-stimulated signaling through G proteins and beta-arrestin. Sci STKE. 2005;2005(311):cm14.
56. Dewire SM, Violin JD. Biased Ligands for Better Cardiovascular Drugs: Dissecting G-Protein-Coupled Receptor Pharmacology. Circ Res. 2011; 109(2):205–216.
57. Felker GM, Butler J, Collins SP, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Failure. 2015;3(3):193–201.
58. Ferrario CM, Schiffrin EL. Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. Circ Res. 2015;116(1):206–213.
59. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest. 2000;106(1):103–106.
60. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hyper-trophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62(4):749–756.
61. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38(3 Pt 2): 581–587.
62. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53–57.
63. van de Wal RMA, Plokker HWM, Lok DJA, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106(3):367–372.
64. Doerschug KC, Delsing AS, Schmidt GA, Ashare A. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Critical Care. 2010;14(1):R24.
65. Antonucci E, Gleeson PJ, Annoni F, et al. Angiotensin II in Refractory Septic Shock. Shock. 2017;47(5):560–566.
66. Landry DW, Oliver JA. The Pathogenesis of Vasodilatory Shock. N Engl J Med Overseas Ed. 2001;345(8):588–595.
67. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev. 1997; 77(4):1165–1232.
68. Zhang WEI, Chen X, Huang L, et al. Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med. 2014;7(5):1342–1348.
69. Dong LW, Chang YZ, Tong LJ, Tang J, Jy S, Tang CS. Role of regulatory peptide in pathogenesis of shock. Science in China Series B, Chemistry, Life Sciences & Earth Sciences. 1994;37(2):162–169.
70. Dunn CW, Horton JW. Role of angiotensin II in neonatal sepsis. Circ Shock. 1993;40(2):144–150.
71. Casey L, Krieger B, Kohler J, Rice C, Oparil S, Szidon P. Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report. Crit Care Med. 1981;9(9):651–654.
72. Orfanos SE, Armaganidis A, Glynos C, et al. Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury. Circulation. 2000;102(16):2011–2018.
73. Schmidt C, Höcherl K, Kurt B, Moritz S, Kurtz A, Bucher M. Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine. 2010;49(1):30–38.
74. Bucher M, Hobbhahn J, Kurtz A. Nitric oxide-dependent downregulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med. 2001;29(9):1750–1755.
75. Bucher M, Ittner K-P, Hobbhahn J, Taeger K, Kurtz A. Downregulation of Angiotensin II Type 1 Receptors During Sepsis. Hypertension. 2001;38(2):177–182.
76. Wolf RL, Mendlowitz M, Gitlow SE, Naftchi N. Metabolism of Angiotensin II-I131 in Normotensive and Hypertensive Human Subjects. Circulation. 1961;23(5):754–758.
77. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14(6): 799–805.
78. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Menard J. Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives. Circulation. 1995;92(4): 825–834.
79. Wunderink RA, Busse T, Deane L, et al. Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II. Intensive Care Medicine Experimental. 2017;5(Suppl 2):0703.
80. Rosenfeld CR, Naden RP. Uterine and nonuterine vascular responses to angiotensin II in ovine pregnancy. Am J Physiol Heart Circ Physiol. 1989;257(1):H17–H24.
81. Ramin SM, Ramin KD, Cox K, Magness RR, Shearer VE, Gant NF. Comparison of prophylactic angiotensin II versus ephedrine infusion for prevention of maternal hypotension during spinal anesthesia. Am J Obstet Gynecol. 1994;171(3):734–739.
82. Naden RP, Rosenfeld CR. Effect of angiotensin II on uterine and systemic vasculature in pregnant sheep. J Clin Invest. 1981;68(2):468–474.
83. Vincent RD, Werhan CF, Norman PF, et al. Prophylactic Angiotensin II Infusion during Spinal Anesthesia for Elective Cesarean Delivery. Anesthesiology. 1998;88(6):1475–1479.
84. Conti C, Tranquilli AL, Garzetti GG, Romanini C. Modulation of vascular reactivity after acute calcium antagonist administration in pregnant women moderately sensitive to angiotensin infusion. Bollettino della Societa italiana di biologia sperimentale. 1994;70(10–11):243–248.
85. Öney T, Kaulhausen H. The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy. Am J Obstet Gynecol. 1982;142(1):17–20.
86. Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. The Lancet. 1993;341(8846):703.
87. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II [letter]. Br J Clin Pharmacol. 1995;40(1):103–104.
88. Trilli LE, Johnson KA. Lisinopril Overdose and Management with Intravenous Angiotensin II. Ann Pharmacother. 1994;28(10):1165–1168.
89. Kato T, Murakami Y, Saito Y, et al. New modality of radiation therapy under increased tumor oxygen tension with angiotensin II: a pilot study. Radiat Med. 1993;11(3):86–90.
90. Sato H, Sugiyama K, Hoshi M, Urushiyama M, Ishizuka K. Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: With reference to resection after down staging. World J Surg. 1995;19(6):836–842.
91. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol. 2009;39(11):756–766.
92. Tomura N, Kato T, Kanno I, et al. Increased blood flow in human brain tumor after administration of angiotensin II: demonstration by PET. Comput Med Imaging Graph. 1993;17(6):443–449.
93. Millar EA, Angus RM, Hulks G, Morton JJ, Connell JM, Thomson NC. Activity of the renin-angiotensin system in acute severe asthma and the effect of angiotensin II on lung function. Thorax. 1994;49(5): 492–495.
94. Millar EA, Nally JE, Thomson NC. Angiotensin II potentiates methacholine-induced bronchoconstriction in human airway both in vitro and in vivo. Eur Respir J. 1995;8(11):1838–1841.
95. Ramsay SG, Clayton RA, Dagg KD, Thomson LJ, Nally JE, Thomson NC. Effect of angiotensin II on histamine-induced bronchoconstriction in the human airway both in vitro and in vivo. Respir Med. 1997; 91(10):609–615.
96. Cohn JN, Luria MH. Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin. J Clin Invest. 1965;44(9):1494–1504.
97. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44(7):1171–1186.
98. Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Medicine. 2017;43(6):730–749.
99. Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med Overseas Ed. 2016;375(2):122–133.
100. Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically Ill patients with acute kidney injury. JAMA. 2016;315(20):2190–2199.
101. Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011;22(6):999–1006.
102. Langenberg C, Bagshaw SM, May CN, Bellomo R. The histopathology of septic acute kidney injury: a systematic review. Crit Care. 2008;12(2):R38.
103. Lankadeva YR, Kosaka J, Evans RG, Bailey SR, Bellomo R, May CN. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. Kidney Int. 2016;90(1): 100–108.
104. Chen H, Busse LW. Novel therapies for acute kidney injury. Kidney Int Rep. 2017;2(5):785–799.
105. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004;114(1): 5–14.
106. Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care. 2009;13(6):R190.
107. Herget-Rosenthal S, Saner F, Chawla LS. Approach to hemodynamic shock and vasopressors. Clin J Am Soc Nephrol. 2008;3(2): 546–553.
108. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. JAMA. 2016;316(5): 509–518.
109. Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007;357(8):797–805.
110. Prowle JR, Bellomo R. Sepsis-associated acute kidney injury: mac-rohemodynamic and microhemodynamic alterations in the renal circulation. Semin Nephrol. 2015;35(1):64–74.
111. Lankadeva YR, Kosaka J, Evans RG, Bellomo R, May CN. Urinary Oxygenation as a Surrogate Measure of Medullary Oxygenation During Angiotensin II Therapy in Septic Acute Kidney Injury. Crit Care Med. 2018;46(1):e41–e48.
112. Brenner M, Schaer GL, Mallory DL, Suffredini AF, Parrillo JE. Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest. 1990;98(1):170–179.
113. Thomas VL, Nielsen MS. Administration of angiotensin II in refractory septic shock. Crit Care Med. 1991;19(8):1084–1085.
114. Tovar JL, Bujons I, Ruiz JC, Ibañez L, Salgado A. Treatment of severe combined overdose of calcium antagonists and converting enzyme inhibitors with angiotensin II. Nephron. 1997;77(2):239.
115. Wray GM, Coakley JH. Severe septic shock unresponsive to nora-drenaline. Lancet. 1995;346(8990):1604.
116. Suberviola B, Rodrigo E, González-Castro A, Serrano M, Heras M, Castellanos-Ortega Á. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury. Med Intensiva. 2017; 41(1):21–27.
117. Corrêa TD, Takala J, Jakob SM. Angiotensin II in septic shock. Crit Care. 2015;19:98.
118. Umbrello M, Formenti P, Bolgiaghi L, Chiumello D. Current Concepts of ARDS: A Narrative Review. Int J Mol Sci. 2016;18(1):64.
119. Ryan JW. Processing of endogenous polypeptides by the lungs. Annu Rev Physiol. 1982;44:241–255.
120. Orfanos SE, Langleben D, Khoury J, et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation. 1999;99(12):1593–1599.
121. Busse LA, Gong T, Thompson M. Outcomes in patients with acute respiratory distress syndrome receiving angiotensin II for vasodilatory shock. Critical Care. 2018;22(Suppl 1):82.
122. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–2533.
123. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.
124. Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol. 2008;75(4):781–786.
125. Wang G, Zhang Q, Yuan W, Wu J, Li C. Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation. Int J Mol Med. 2016;38(5):1463–1473.
126. Arnal JF, Cudek P, Plouin PF, Guyenne TT, Michel JB, Corvol P. Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure: implications for renin measurements. Am J Med. 1991;90(1):17–22.
127. Imai M, Sokabe H. Plasma renin and angiotensinogen levels in pathological states associated with oedema. Arch Dis Child. 1968; 43(230):475–479.
128. Faymonville ME, Larbuisson R, Radermecker M, Limet R, Fourny J, Lamy M. Serum activity of angiotensin converting enzyme during extracorporeal circulation in man. C R Seances Soc Biol Fil. 1983;177(2): 252–258.
129. Panagiotopoulos I, Palatianos G, Michalopoulos A, Chatzigeorgiou A, Prapas S, Kamper EF. Alterations in biomarkers of endothelial function following on-pump coronary artery revascularization. J Clin Lab Anal. 2010;24(6):389–398.
130. Giapreza. Lexi-Drugs. Lexicomp Online [database online]. Hudson, OH: Lexi-Comp, Inc; 2018. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6582570. Accessed March 26, 2018.
131. Busse LA, Gong T, Thompson M. Outcomes in patients with acute respiratory distress syndrome receiving angiotensin II for vasodilatory shock. Critical Care. 2018;22(Suppl 1):82.